ARVC, or arrhythmogenic right ventricular cardiomyopathy, is a genetic heart disease in dogs where normal heart muscle is gradually replaced by fatty or fibrous tissue. This replacement disrupts the heart’s electrical signals, causing dangerous irregular rhythms that can lead to fainting, collapse, or sudden death. It is overwhelmingly a disease of Boxer dogs, though English Bulldogs are also affected.
What Happens Inside the Heart
ARVC is fundamentally a disease of desmosomes, the protein structures that glue heart muscle cells together. When desmosomes malfunction, heart muscle cells lose their connections, weaken, and die. The body replaces those lost cells with fat and scar tissue rather than new muscle.
This process primarily affects the right ventricle, the chamber that pumps blood to the lungs. As fatty and fibrous tissue accumulates, it creates electrical “short circuits” in the heart wall. These short circuits trigger ventricular arrhythmias, where the lower chambers of the heart fire erratically instead of beating in a steady rhythm. In about a third of affected dogs, the right ventricle also dilates (stretches out), further weakening its ability to pump.
Three Stages of the Disease
ARVC typically progresses through three recognizable phases, though not every dog moves through all of them.
- Concealed (occult) stage: The dog appears completely healthy. Abnormal heart rhythms may already be present but produce no visible symptoms. Dogs in this stage can still experience sudden cardiac death with no prior warning.
- Overt arrhythmia stage: The dog develops fainting episodes, weakness during exercise, or collapse. This is the stage where most dogs are diagnosed. Roughly 80 to 85 percent of Boxer dogs diagnosed with ARVC show fainting or near-fainting as a presenting sign.
- Heart failure stage: A smaller number of dogs progress to congestive heart failure, where the weakened right ventricle can no longer pump effectively. This can cause fluid buildup in the abdomen, labored breathing, and significant exercise intolerance.
Signs to Watch For
The most common and often the first noticeable sign is fainting (syncope) or near-fainting, where the dog’s legs buckle or it collapses briefly but doesn’t fully lose consciousness. These episodes tend to happen during excitement, exercise, or exertion. Some dogs recover within seconds and act normal immediately afterward, which can make the event easy to dismiss.
Other signs include exercise intolerance (tiring faster than usual on walks or during play), a racing or irregular heartbeat that you might feel by placing your hand on the dog’s chest, and in advanced cases, a swollen abdomen from fluid retention. Some dogs, however, show no symptoms at all before a fatal arrhythmia. This is what makes the concealed stage so dangerous.
Which Breeds Are Affected
Boxers are by far the most commonly affected breed. The disease was first formally described in Boxers in the early 1980s, and pedigree analysis has traced affected lines in both the United States and the United Kingdom back to a small group of imported American dogs. English Bulldogs, a breed closely related to Boxers, also develop the condition. Reports in other breeds exist but are rare and less well studied.
The Genetics Behind ARVC
ARVC in Boxers is inherited in an autosomal dominant pattern with incomplete penetrance. “Autosomal dominant” means a dog only needs one copy of the faulty gene (from one parent) to be at risk. “Incomplete penetrance” means that not every dog carrying the mutation will develop clinical disease, and those that do may develop it at different ages and with different severity.
Two genetic mutations are currently associated with the disease: ARVC1 (in the striatin gene) and ARVC2 (in the FOS gene). The genetics are more complex than initially thought. Pedigree research has shown that the striatin mutation itself is likely not the direct cause of ARVC but sits close to the responsible gene on the same chromosome, acting as a marker rather than a trigger. Dogs without the striatin mutation can still develop ARVC, and dogs with the mutation can remain healthy.
North Carolina State University’s veterinary genetics lab offers testing for both mutations. Dogs positive for both ARVC1 and ARVC2 appear to be at higher risk, and dogs that are homozygous (carrying two copies of a mutation) tend to develop more severe disease. A negative result, however, does not guarantee a dog will never develop ARVC, since other as-yet-unidentified genetic factors may contribute.
How ARVC Is Diagnosed
The gold standard for diagnosis is a Holter monitor, a small device worn on the dog’s body that records every heartbeat over a 24-hour period. This captures arrhythmias that may not be happening during a brief vet visit. Finding more than 100 ventricular premature contractions (extra beats originating from the ventricles) in 24 hours in an adult Boxer is strongly suggestive of ARVC, especially when those extra beats come in pairs, runs, or other complex patterns.
A standard in-clinic ECG can catch arrhythmias if they happen to occur during the recording, but it only captures a few minutes of activity and often misses intermittent abnormalities. Echocardiography (heart ultrasound) is useful for detecting structural changes like right ventricular dilation, but many dogs with ARVC have a heart that looks structurally normal on ultrasound, particularly in the early stages. That’s why Holter monitoring is so important: it catches the electrical problem even when the physical appearance of the heart hasn’t changed yet.
For Boxers, veterinary cardiologists often recommend periodic Holter monitoring starting around age 3 or 4, especially for dogs in breeding programs or those with a family history of the disease.
Treatment and Management
There is no cure for ARVC. Treatment focuses on controlling the dangerous heart rhythms and reducing the risk of sudden death. Anti-arrhythmic medications are the primary tool. Sotalol, a drug that slows and stabilizes the heart’s electrical activity, is commonly used. For dogs that also develop heart failure, mexiletine combined with a low-dose beta-blocker is often preferred, since sotalol alone can worsen heart failure.
The goal of medication is to reduce the number and severity of abnormal heartbeats. Your vet will typically do a follow-up Holter monitor after starting medication to check whether the drug is working. Dosages may need adjustment over time as the disease progresses.
Dogs with ARVC are generally advised to avoid intense exercise and high-excitement situations, since both can trigger dangerous arrhythmias. Moderate, calm activity is usually considered acceptable, but the specifics depend on the individual dog’s arrhythmia burden.
Prognosis and Survival
The outlook for dogs with ARVC is more encouraging than many owners expect. A prospective study tracking Boxer dogs over time found that dogs diagnosed with ARVC had a median survival of 11 years of age, compared to 10 years in the control group without the disease. Even after detection of significant arrhythmia (300 or more abnormal beats per day), the median survival was about 1,528 days, roughly four years. Dogs with more than 1,000 abnormal beats per day had a similar median survival of about 1,754 days.
These numbers come with a caveat: many of the dogs in the study were receiving anti-arrhythmic medication, and the study wasn’t designed to separate the effect of treatment from the natural course of the disease. Still, the data suggest that a diagnosis of ARVC does not necessarily mean a dramatically shortened life. The greatest risk is sudden cardiac death from an unpredictable fatal arrhythmia, which can occur at any stage, including before the disease is ever detected.
Genetic Testing and Breeding Decisions
Genetic testing is a practical tool for Boxer breeders. Dogs that test positive for either ARVC1 or ARVC2 (or both) are at increased risk of developing the disease and will pass at least one copy of the mutation to their offspring. Dogs that are homozygous for a mutation will pass a copy to every single puppy. Breeding decisions based on test results, combined with Holter screening, can help reduce the prevalence of ARVC in future generations.
For pet owners, genetic testing can guide monitoring decisions. A positive result means more vigilant cardiac screening over the dog’s lifetime. A negative result is reassuring but not a guarantee, since the known mutations don’t account for every case. Holter monitoring remains the most reliable way to catch the disease regardless of genetic status.